Date: 2014-12-01
Type of information: Licensing agreement
Compound: tenofovir alafenamide
Company: Gilead Sciences (USA - CA) Mylan (USA - PA)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: HIV-1 infection
Details: * On December 1, 2014, Mylan announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences,under which Mylan has licensed the non-exclusive rights to manufacture and distribute tenofovir alafenamide (TAF) as both a single agent product and in combination with other drugs. Tenofovir Alafenamide (TAF) is an investigational antiretroviral drug for the treatment of HIV-1 infection. The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally. As part of the licensing agreement, on FDA approval, Mylan will receive a technology transfer from Gilead, enabling the company to manufacture low-cost versions of Tenofovir Alafenamide (TAF), if approved as a single agent or in approved combinations containing Tenofovir Alafenamide (TAF) for developing markets.
Financial terms:
Latest news:
